Precision Medicine in Solid Tumors
In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy....
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (304 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993560444704498 |
---|---|
ctrlnum |
(CKB)5680000000080745 (oapen)https://directory.doabooks.org/handle/20.500.12854/92020 (EXLCZ)995680000000080745 |
collection |
bib_alma |
record_format |
marc |
spelling |
Dey, Nandini edt Precision Medicine in Solid Tumors Basel MDPI Books 2022 1 electronic resource (304 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines. English Medicine bicssc Oncology bicssc pediatric tumors tumor mutational burden TMB whole-exome sequencing gene panel sequencing immune checkpoint inhibitors glioblastoma prognosis overall survival extent of resection random forest Decision tree personalized precision oncology circulating free DNA liquid biopsy epidermal growth factor receptor tyrosine kinase inhibitor osimertinib comprehensive genomic profiling molecular genotyping intratumor heterogeneity multiple biopsies tumor evolution clonality classification strategic therapeutic intervention thymoma driver mutation sequencing molecular barcoding EGFR mutation EGFR-TKI cfDNA NGS digital enrichment next-generation sequencing solid cancer universal health-care system precision medicine presumed germline findings clinical guideline non-small cell lung cancer outcome adjuvant chemotherapy anaplastic lymphoma receptor tyrosine kinase HNSCC ctDNA tDNA DDR genes PARP inhibitors new drug development next-generation sequencing (NGS) open data regulatory reform tumor profiling test triple-negative breast cancer (TNBC) breast cancer targeted therapy TNBC subtypes immunotherapy cancer screening smoking electronic records PD-L1 cancer-associated fibroblasts resistance chemotherapy CTC immunocytochemistry parallel double-detection laboratory-friendly 3-0365-4791-6 3-0365-4792-4 De, Pradip edt Dey, Nandini oth De, Pradip oth |
language |
English |
format |
eBook |
author2 |
De, Pradip Dey, Nandini De, Pradip |
author_facet |
De, Pradip Dey, Nandini De, Pradip |
author2_variant |
n d nd p d pd |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Precision Medicine in Solid Tumors |
spellingShingle |
Precision Medicine in Solid Tumors |
title_full |
Precision Medicine in Solid Tumors |
title_fullStr |
Precision Medicine in Solid Tumors |
title_full_unstemmed |
Precision Medicine in Solid Tumors |
title_auth |
Precision Medicine in Solid Tumors |
title_new |
Precision Medicine in Solid Tumors |
title_sort |
precision medicine in solid tumors |
publisher |
MDPI Books |
publishDate |
2022 |
physical |
1 electronic resource (304 p.) |
isbn |
3-0365-4791-6 3-0365-4792-4 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT deynandini precisionmedicineinsolidtumors AT depradip precisionmedicineinsolidtumors |
status_str |
n |
ids_txt_mv |
(CKB)5680000000080745 (oapen)https://directory.doabooks.org/handle/20.500.12854/92020 (EXLCZ)995680000000080745 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Precision Medicine in Solid Tumors |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796652159279824896 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04947nam-a2201165z--4500</leader><controlfield tag="001">993560444704498</controlfield><controlfield tag="005">20231214133243.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202209s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000080745</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/92020</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000080745</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dey, Nandini</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Precision Medicine in Solid Tumors</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI Books</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (304 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pediatric tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor mutational burden</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TMB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">whole-exome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene panel sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">overall survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extent of resection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">random forest</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Decision tree</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized precision oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circulating free DNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epidermal growth factor receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">osimertinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comprehensive genomic profiling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular genotyping</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intratumor heterogeneity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multiple biopsies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clonality classification</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">strategic therapeutic intervention</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thymoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">driver mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular barcoding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EGFR mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EGFR-TKI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cfDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NGS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">digital enrichment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">next-generation sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solid cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">universal health-care system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">precision medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">presumed germline findings</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical guideline</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-small cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anaplastic lymphoma receptor tyrosine kinase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HNSCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ctDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DDR genes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PARP inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">new drug development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">next-generation sequencing (NGS)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">open data</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory reform</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor profiling test</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triple-negative breast cancer (TNBC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNBC subtypes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">smoking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">electronic records</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer-associated fibroblasts</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CTC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunocytochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">parallel double-detection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">laboratory-friendly</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4791-6</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4792-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De, Pradip</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dey, Nandini</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De, Pradip</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:47:58 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5340302880004498&Force_direct=true</subfield><subfield code="Z">5340302880004498</subfield><subfield code="b">Available</subfield><subfield code="8">5340302880004498</subfield></datafield></record></collection> |